An immuno-DOT diagnostic assay for autoimmune nodopathy.

IF 3.8 2区医学 Q1 MEDICAL LABORATORY TECHNOLOGY

Clinical chemistry and laboratory medicine Pub Date : 2024-06-12 DOI:10.1515/cclm-2024-0510

Alexandre Jentzer, Guillaume Taieb, Jérémie El Bechir, Thierry Vincent, Jérôme Joël Devaux

{"title":"An immuno-DOT diagnostic assay for autoimmune nodopathy.","authors":"Alexandre Jentzer, Guillaume Taieb, Jérémie El Bechir, Thierry Vincent, Jérôme Joël Devaux","doi":"10.1515/cclm-2024-0510","DOIUrl":null,"url":null,"abstract":"Objectives: Autoimmune nodopathy (AN) is a life-threatening peripheral neuropathy mediated by four autoantibodies targeting axoglial cell adhesion molecules at the nodes of Ranvier: Neurofascin-155 (Nfasc155), PanNeurofascin (PanNfasc), Contactin-1 (CNTN1), and Contactin-associated protein 1 (CASPR1). Antibody detection is a strong biomarker for AN diagnosis and treatment monitoring. The aim of this study was to develop an immuno-dot assay (immuno-DOT) compatible with routine implementation in medical laboratories.Methods: This new approach was compared to standard techniques: indirect immunofluorescence assay, cell-based assay, and ELISA. Sensitivities (Se) and specificities (Sp) were calculated on a cohort composed of 58 patients diagnosed with AN, 50 seronegative patients with chronic inflammatory demyelinating polyradiculoneuropathy, 20 healthy controls, 30 patients with Guillain-Barré syndrome, 20 with monoclonal gammopathy and 20 with Charcot-Marie-Tooth disease. The patients were diagnosed with AN based on compatible electro-clinical arguments and at least two positive standard techniques.Results: Immuno-DOT sensitivities and specificities were Se=91 %, Sp=97 % for anti-Nfasc155; Se=80 %, Sp=94 % for anti-PanNfasc; Se=93 %, Sp=98 % for anti-CNTN1; and Se=87 %, Sp=94 % for anti-CASPR1. Immuno-DOT allowed the diagnosis within 3 h and the accurate follow-up of the immune reactivity and isotype, and dot intensity correlated with antibody titers following treatments. A longitudinal study indicated that immuno-DOT yielded reliable results even after six months of storage at -20 °C.Conclusions: The diagnostic performance of immuno-DOT was satisfactory and compatible with routine implementation in medical laboratories.","PeriodicalId":10390,"journal":{"name":"Clinical chemistry and laboratory medicine","volume":null,"pages":null},"PeriodicalIF":3.8000,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical chemistry and laboratory medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1515/cclm-2024-0510","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Autoimmune nodopathy (AN) is a life-threatening peripheral neuropathy mediated by four autoantibodies targeting axoglial cell adhesion molecules at the nodes of Ranvier: Neurofascin-155 (Nfasc155), PanNeurofascin (PanNfasc), Contactin-1 (CNTN1), and Contactin-associated protein 1 (CASPR1). Antibody detection is a strong biomarker for AN diagnosis and treatment monitoring. The aim of this study was to develop an immuno-dot assay (immuno-DOT) compatible with routine implementation in medical laboratories.

Methods: This new approach was compared to standard techniques: indirect immunofluorescence assay, cell-based assay, and ELISA. Sensitivities (Se) and specificities (Sp) were calculated on a cohort composed of 58 patients diagnosed with AN, 50 seronegative patients with chronic inflammatory demyelinating polyradiculoneuropathy, 20 healthy controls, 30 patients with Guillain-Barré syndrome, 20 with monoclonal gammopathy and 20 with Charcot-Marie-Tooth disease. The patients were diagnosed with AN based on compatible electro-clinical arguments and at least two positive standard techniques.

Results: Immuno-DOT sensitivities and specificities were Se=91 %, Sp=97 % for anti-Nfasc155; Se=80 %, Sp=94 % for anti-PanNfasc; Se=93 %, Sp=98 % for anti-CNTN1; and Se=87 %, Sp=94 % for anti-CASPR1. Immuno-DOT allowed the diagnosis within 3 h and the accurate follow-up of the immune reactivity and isotype, and dot intensity correlated with antibody titers following treatments. A longitudinal study indicated that immuno-DOT yielded reliable results even after six months of storage at -20 °C.

Conclusions: The diagnostic performance of immuno-DOT was satisfactory and compatible with routine implementation in medical laboratories.

查看原文本刊更多论文

自身免疫性结节病的免疫 DOT 诊断测定。

目的：自身免疫性结节病（AN）是一种危及生命的周围神经病，由四种针对Ranvier结处轴突胶质细胞粘附分子的自身抗体介导：Neurofascin-155（Nfasc155）、PanNeurofascin（PanNfasc）、Contactin-1（CNTN1）和Contactin相关蛋白1（CASPR1）。抗体检测是 AN 诊断和治疗监测的一个强有力的生物标志物。本研究的目的是开发一种可在医学实验室中常规使用的免疫点检测法（immuno-DOT）：方法：将这种新方法与标准技术（间接免疫荧光检测法、细胞检测法和酶联免疫吸附法）进行比较。计算了一组患者的敏感性（Se）和特异性（Sp），这些患者包括58名被诊断为AN的患者、50名血清阴性的慢性炎症性脱髓鞘多发性神经病患者、20名健康对照组患者、30名格林-巴利综合征患者、20名单克隆丙种球蛋白病患者和20名夏科-玛丽-牙病患者。这些患者被诊断为AN的依据是符合的电-临床论据和至少两项阳性标准技术：抗Nfasc155的免疫DOT敏感性和特异性分别为Se=91 %，Sp=97 %；抗PanNfasc的敏感性和特异性分别为Se=80 %，Sp=94 %；抗CNTN1的敏感性和特异性分别为Se=93 %，Sp=98 %；抗CASPR1的敏感性和特异性分别为Se=87 %，Sp=94 %。免疫点滴试验可在 3 小时内做出诊断，并准确跟踪免疫反应性和同种型，点滴强度与治疗后的抗体滴度相关。一项纵向研究表明，即使在-20 °C下保存6个月，免疫点滴试验也能得出可靠的结果：免疫-DOT的诊断性能令人满意，可在医学实验室中常规使用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical chemistry and laboratory medicine 医学-医学实验技术

CiteScore

11.30

自引率

16.20%

发文量

306

审稿时长

3 months

期刊介绍： Clinical Chemistry and Laboratory Medicine (CCLM) publishes articles on novel teaching and training methods applicable to laboratory medicine. CCLM welcomes contributions on the progress in fundamental and applied research and cutting-edge clinical laboratory medicine. It is one of the leading journals in the field, with an impact factor over 3. CCLM is issued monthly, and it is published in print and electronically. CCLM is the official journal of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) and publishes regularly EFLM recommendations and news. CCLM is the official journal of the National Societies from Austria (ÖGLMKC); Belgium (RBSLM); Germany (DGKL); Hungary (MLDT); Ireland (ACBI); Italy (SIBioC); Portugal (SPML); and Slovenia (SZKK); and it is affiliated to AACB (Australia) and SFBC (France). Topics: - clinical biochemistry - clinical genomics and molecular biology - clinical haematology and coagulation - clinical immunology and autoimmunity - clinical microbiology - drug monitoring and analysis - evaluation of diagnostic biomarkers - disease-oriented topics (cardiovascular disease, cancer diagnostics, diabetes) - new reagents, instrumentation and technologies - new methodologies - reference materials and methods - reference values and decision limits - quality and safety in laboratory medicine - translational laboratory medicine - clinical metrology Follow @cclm_degruyter on Twitter!